China: Biopharmaceuticals Boehringer Ingelheim to Expand Manufacturing Capacity of Biologics
The expansion will be carried out at the firm’s Oasis facility which will also witness its first commercial production and supply of the monoclonal antibody drug. The expansion includes an additional bioreactor along with all the required utility and infrastructure to support the GMP operations.
Shanghai/China – Boehringer Ingelheim has recently announced that it has initiated a capacity expansion at its commercial manufacturing site for biologics in China. The expansion covers an additional bioreactor and includes all needed utility and infrastructure to support the GMP operations of 2x 2.000L single use bioreactor manufacturing lines.
The company’s biopharmaceutical contract manufacturing business is expected to begin manufacturing the commercial supply of a monoclonal antibody out of its China manufacturing Oasis facility in 2019. This will be the first commercial drug manufactured in the Shanghai facility, Oasis, an important part of Boehringer Ingelheim’s global biopharmaceutical production network. Following the commercial manufacturing of a client’s antibody, a number of investigational drugs are in the firm’s contract manufacturing business pipeline for potential future market launch and commercial supply out of Shanghai, China.